



NIH PUBLIC ACCESS

Author Manuscript

J Med Chem. Author manuscript; available in PMC 2012 August 10.

Published in final edited form as:

J Med Chem. 2009 November 12; 52(21): 6814–6821. doi:10.1021/jm900715m.

The Effects of C-terminal Modifications on the Opioid Activity of [N-BenzylTyr¹]Dynorphin A-(1-11) Analogs

Kshitij A. Patkar[†], Thomas F. Murray[‡], and Jane V. Aldrich^{†,*}Jane V. Aldrich: jaldrich@ku.edu[†]Department of Medicinal Chemistry, University of Kansas, Lawrence, 66045[‡]Department of Pharmacology, Creighton University School of Medicine, Omaha, NE 68178

Abstract

Structural modifications affecting the efficacy of analogs of the endogenous opioid peptide dynorphin (Dyn) A have focused on the N-terminal “message” sequence, based on the “message-address” concept. To test the hypothesis that changes in the C-terminal “address” domain could affect efficacy, modified amino acids and cyclic constraints were incorporated into this region of the partial agonist [N-benzylTyr¹]Dyn A-(1-11). Modifications in the C-terminal domain of [N-benzylTyr¹]Dyn A-(1-11)NH₂ resulted in increased kappa opioid receptor (KOR) affinity for all of the linear analogs, but did not affect the efficacy of these peptides at KOR. Cyclization between positions 5 and 8 yielded [N-benzylTyr¹,cyclo(D-Asp⁵,Dap⁸)]Dyn A-(1-11)NH₂ (**13**) (Patkar et al. *J. Med. Chem.* **2005**, 48, 4500-4503) with high selectivity for KOR. In contrast to the linear peptides, this peptide exhibits negligible efficacy in the AC assay and is a KOR antagonist. These data are consistent with our hypothesis that appropriate modifications in the “address” domain of Dyn A analogs may affect efficacy.

Introduction

Narcotic analgesics that target μ opioid receptors (MOR) have been used extensively in the clinical management of pain,¹ but their use is complicated by serious side effects.² Thus there has been considerable interest in the development of ligands for kappa opioid receptors (KOR) as potential therapeutic agents for pain and other disorders.³ KOR agonists can produce analgesia with less addiction liability and respiratory depression than MOR agonists,^{4,5} and compounds with KOR agonist activity are used clinically (e.g. pentazocine). However, KOR agonists can also cause dysphoria in humans.⁶ In addition to the centrally mediated analgesia, KOR agonists can produce antinociception through peripheral KOR,⁷ and peripherally selective KOR agonists are in clinical trials as analgesics.⁸ Moreover, KOR agonists also exhibit anti-inflammatory activity.⁹ Other potentially useful therapeutic effects of KOR agonists include anticonvulsant and neuroprotective effects and their ability to down-regulate HIV-1 expression in human microglial and CD₄ cells (see ref. ¹⁰ for a review). KOR antagonists, initially used only as pharmacological tools, also have potential therapeutic uses in the treatment of depression,¹¹⁻¹³ anxiety,^{14, 15} and opiate and cocaine addiction.^{12, 16, 17} The KOR selective peptide antagonist arodyn¹⁸ designed in our laboratory suppresses stress-induced reinstatement of cocaine seeking behavior in mice,¹⁷ suggesting its potential use in the development of peptide-based therapeutics for the treatment of cocaine addiction.

*To whom the correspondence should be addressed. Tel. (785) 864 2287, fax (785) 864 5326, jaldrich@ku.edu.

Supporting Information Details of the synthesis of N-benzyltyrosine and analytical data for the peptides. This material is available free of charge via the Internet at <http://pubs.acs.org>.

The heptadecapeptide dynorphin (Dyn) A (Figure 1) is an endogenous agonist for KOR.¹⁹ Studies of Dyn A and its fragments by Chavkin and Goldstein led them to propose the “message-address” concept in which the four N-terminal amino acids in Dyn A are the “message” sequence responsible for opioid agonist activity and the C-terminal domain is the “address” that enhances the affinity of this peptide for KOR.²⁰ The entire C-terminal sequence is not required for KOR interaction, however, and the first 11-13 residues of Dyn A account for essentially all of the opioid activity of the longer peptide.²⁰

We are interested in exploring the structural features of Dyn A that affect efficacy and result in peptide antagonists for KOR. Structural modifications in the N-terminus of Dyn A can alter efficacy as well as potency and selectivity. Alkylation of the N-terminus can influence both KOR affinity and efficacy. While the *N,N*-diallylTyr¹ analogs of [D-Pro¹⁰]Dyn A-(1-11) and Dyn A-(1-13) exhibit antagonist activity at KOR and MOR²¹⁻²³ (but with decreased binding affinity and selectivity for KOR compared to the parent peptides without the N-terminal modification), the monoalkylated derivatives have high KOR affinity and selectivity.^{23, 24} The *N*-allyl- and *N*-cyclopropylmethyl (CPM) analogs are potent agonists in the guinea pig ileum (GPI) assay, while the *N*-benzyl analog exhibits weak agonist activity in the GPI assay^{23, 24} and is a partial agonist in the adenylyl cyclase (AC) assay using cloned KOR expressed on Chinese hamster ovary (CHO) cells.²⁵ Other modifications in the N-terminal sequence of Dyn A-(1-11) analogs that result in antagonist activity at KOR are Pro in the position 3,²⁶ and the removal of the basic α -amine of Tyr¹ in analogs such as dynantin.²⁷ Other analogs with antagonist activity, namely JVA-901,²⁸ arodyn¹⁸ and *cyclo*^{N:5}[Trp³,Trp⁴,Glu⁵]Dyn A-(1-11)NH₂,²⁹ prepared in our laboratory also lack a basic N-terminus.

Reports in the literature examining modifications in the C-terminal or “address” sequence of Dyn A suggest that in selected cases such modifications may affect the efficacy of these analogs at KOR. While analogs of [Phe¹]Dyn A-(1-11)NH₂ with D-Ala⁸ and D-Pro¹⁰ substitutions retain similar KOR affinity (<50% difference), they exhibit large differences in potency in the GPI³⁰ (almost a 50-fold decrease for the D-Ala⁸ analog compared to the parent peptide). Such discrepancies in affinity and potency suggest a possible role of the C-terminus in the efficiency of receptor activation. A variety of cyclic analogs of Dyn A, cyclized either with a disulfide or lactam linkage, have been prepared to restrict conformational freedom and study possible bioactive conformations (see refs. ^{3, 31} for reviews). Interestingly, some of these analogs also display discrepancies between KOR affinity and potency in the GPI. Cyclic analogs with disulfide linkages between residues 5 and 11 ([5,11]), which may stabilize a reverse turn in the C-terminal region of Dyn A-(1-13)NH₂, were reported to possess high KOR affinity in brain homogenate but low potency in the GPI assay, which the authors suggested could be due to different interactions with central vs. peripheral KOR.³² Similarly, a series of lactam bridged [5,8] cyclic analogs of Dyn A-(1-13)NH₂ with varying ring sizes prepared in our laboratory exhibit much lower potency in the GPI than anticipated based on their binding affinity.³³ Also while the [5,8] cyclic analogs exhibit similar binding affinities for KOR, they varied substantially in potency in the GPI (IC₅₀ = 530 - >5000 nM). Interestingly, a computational model suggests a possible role for the hydrophobic residues Leu⁵ and Ile⁸ in the “address” sequence of Dyn A-(1-10) in KOR activation.³⁴ Molecular simulation of Dyn A-(1-10) bound to KOR suggested that these two residues interact with hydrophobic residues in extracellular loop (EL) 2 of KOR.³⁴ Based on this model, it was proposed that these hydrophobic interactions may play a role in the efficacy and/ or affinity of Dyn A for this receptor. In contrast, [6,9] cyclic analogs exhibit similar KOR affinities and are potent agonists in the GPI (IC₅₀ = 7-46 nM).³³

Based on these results we hypothesized that C-terminal residues and/or the conformation of the C-terminal domain of Dyn A, while not a primary determinant, could affect the efficacy of Dyn A analogs. To explore the possible roles of the C-terminus in efficacy, we introduced a series of modifications into [*N*-benzylTyr¹]Dyn A-(1-11) (Figure 2). This peptide was chosen since [*N*-benzylTyr¹,D-Pro¹⁰]Dyn A-(1-11) exhibits partial agonist activity in the AC assay (71% relative to Dyn A-(1-13)NH₂),²⁵ and therefore we could readily detect changes in efficacy. We anticipated that selected changes in the C-terminal domain of the peptide [*N*-benzylTyr¹]Dyn A-(1-11) could alter the efficacy of these analogs at KOR. Since the basic residues in the C-terminal sequence of Dyn A were thought to be important in KOR interaction,²⁰ the modifications were mainly carried out in the non-basic residues in the “address”. Based on the results with [Phe¹]Dyn A-(1-11)NH₂ analogs discussed above, we chose D-Ala⁸ and D-Pro¹⁰ as modifications to incorporate into the C-terminal domain. In order to retain the important Arg side chain but introduce a modification that could alter peptide backbone conformation *N*-MeArg was also incorporated in position 7. Based on the lactam bridged cyclic Dyn A analogs *cyclo*[D-Asp⁵,Dap⁸]- and *cyclo*[D-Asp⁶,Dap⁹]Dyn A-(1-13)NH₂ synthesized previously in our laboratory,³³ we also examined cyclic constraints between the 5th and 8th and the 6th and 9th positions in the C-terminal domain to evaluate their effect on efficacy at KOR. These analogs were evaluated for their opioid receptor affinity in radioligand binding assays and for opioid activity in the AC assay using cloned KOR stably expressed on CHO cells.²⁵ Among these, the [5,8] cyclic analog [*N*-benzylTyr¹,*cyclo*(D-Asp⁵,Dap⁸)]Dyn A-(1-11)NH₂ (which we have named zyklusin) exhibits negligible efficacy at KOR and acts an antagonist in the AC assay at KOR, as we reported in an earlier communication.³⁵ Here we describe the synthesis and report the pharmacological profiles of the full series of C-terminally modified [*N*-benzylTyr¹]Dyn A-(1-11) analogs.

Chemistry

The peptides were synthesized using the Fmoc (9-fluorenylmethoxycarbonyl) solid phase synthetic strategy (Scheme 1). *N*-Benzyltyrosine was synthesized separately in solution, and then coupled to the peptide sequences. Selective monobenylation of tyrosine *tert*-butyl ester was carried out by reductive amination with benzaldehyde using sodium cyanoborohydride in an acidic solution, followed by deprotection of the *tert*-butyl ester using trifluoroacetic acid (TFA) to give *N*-benzyltyrosine. The Dyn A-(2-11) sequences were assembled on a poly(ethylene glycol)-polystyrene (PEG-PS) resin containing the PAL [Peptide Amide Linker, 5-(4-aminomethyl-3,5-dimethoxyphenoxy)valeric acid] linker for the amides and the PAC [Peptide Acid Linker, (hydroxymethyl)phenoxyacetic acid] linker for the acid derivatives **1**, **3** and **4**, using 2-(1*H*-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU) and *N*-methylmorpholine (NMM) in *N,N*-dimethylformamide (DMF) to couple Fmoc-amino acids to the growing peptide chain.²⁸ The side chain protecting groups used were Pbf (2,2,4,6,7-pentamethyl-dihydrobenzofurane-5-sulfonyl) and Mtr (4-methoxy-2,3,6-trimethylbenzenesulfonyl) for the side chains of Arg and *N*^α-Me-Arg, respectively, and Boc (*t*-butyloxycarbonyl) for Lys. The coupling of Fmoc-Arg(Pbf) at position 6 to *N*^α-Me-Arg(Mtr) at position 7 and the coupling of *N*-benzyltyrosine to the resin-bound Dyn A-(2-11) sequences were carried out using 7-azabenzotriazol-1-yloxytris(pyrrolidino)phosphonium hexafluorophosphate (PyAOP),³⁶ 1-hydroxy-7-azabenzotriazole (HOAt) and *N,N*-diisopropylethylamine (DIEA) in DMF.

The cyclic peptides were assembled (Scheme 2) similar to the linear analogs except that Fmoc-D-Asp(Pip) (Pip = 2-phenylisopropyl) and Fmoc-Dap(Mtt) (Dap = 2,3-diaminopropionic acid and Mtt = 4-methyltrityl) were used in the positions involved in cyclization. The hyperacid-labile Pip³⁷ and Mtt³⁸ protecting groups could be removed by dilute (3%) TFA in the presence of the Boc and other *tert*-butyl type side chain protecting

groups that require stronger acidic conditions for deprotection. The cyclizations between the side-chain carboxylic acid of D-Asp and the side-chain free amine of Dap were carried out using PyAOP, HOAt and DIEA in DMF. The cyclization between D-Asp in the position 6 and Dap in position 9, however, did not go to completion after 48 h, even using 6 equivalents of the coupling reagents, so the remaining unreacted amine was acetylated with N-acetylimidazole and DIEA in DMF (Scheme 2). After cyclization, the remaining amino acids were then coupled to complete the peptide sequences. For the synthesis of the acetylated linear analogs **15** and **16**, Fmoc-D-Asn(Trt) (Trt = trityl) and Fmoc-Dap(Mtt) were used; following deprotection of the Mtt group with dilute TFA, the free amine of Dap was acetylated using N-acetylimidazole in DMF.

The peptides were cleaved from the resin using either reagent B³⁹ or modified reagent K⁴⁰ (when *N*-MeArg(Mtr) was present in the peptide sequence). The crude peptides were purified to 98% by preparative reversed phase HPLC and were analyzed for purity by reversed phase HPLC and their molecular weights confirmed by ESI-MS (see Supporting Information).

Results and discussion

The *N*-benzylTyr¹ Dyn A-(1-11) analogs were evaluated for KOR, MOR, and delta opioid receptor (DOR) affinity in radioligand binding assays (Table 1 and Figure 3) and for efficacy in the adenylyl cyclase (AC) assay using cloned rat KOR stably expressed on CHO cells (Figure 4). *N*-Benzylation of Dyn A-(1-11) and [D-Pro¹⁰]Dyn A-(1-11) resulted in peptides **3** and **4**, respectively, with K_i values of 15 nM for KOR using [³H]diprenorphine as the radioligand. These results are comparable to the results we reported previously for **4** (K_i = 18 nM).²⁵ In contrast to other *N*-alkyl Dyn A analogs, the KOR affinity determined for the [*N*-benzylTyr¹,D-Pro¹⁰]Dyn A-(1-11) (**4**) depends on the radioligand used,²⁵ and the 14-fold decrease upon *N*-benzylation observed here was not found when the KOR affinity of **4** was determined using [³H]bremazocine in guinea pig cerebellum.^{23, 24} *N*-Benzylation of Dyn A-(1-11) (**1**) and Dyn A-(1-11)NH₂ (**2**) resulted in analogs **3** and **5**, respectively, that exhibit 2- to 3-fold increases in KOR vs. MOR selectivity and 3- to 5-fold increases in KOR vs. DOR selectivity compared to **1** and **2** (Table 1) due to greater decreases in the affinities for MOR and DOR compared to those for KOR.

We initially prepared both [*N*-benzylTyr¹]Dyn A-(1-11) acid and amide derivatives (**3** and **5**, respectively) for comparison to [*N*-benzylTyr¹,D-Pro¹⁰]Dyn A-(1-11) (**4**) which we described previously.²³⁻²⁵ Compared to peptide **3**, D-Pro in position 10 did not change the KOR affinity for analog **4** but decreased affinity for DOR, thus improving KOR vs. DOR selectivity. Interestingly, converting the C-terminal acid in analogs **3** and **4** to an amide (peptides **5** and **8**, respectively) increased KOR affinity slightly (2- to 3-fold). EL2 of KOR, which has been implicated in Dyn A affinity and selectivity of KOR,^{34, 41} contains a unique cluster of acidic residues that is not present in human and rodent MOR or DOR.^{42, 43} An increase in the KOR affinity upon amidation may be due to the neutralization of unfavorable interactions between the C-terminal acid with the acidic residues on the EL2 of KOR. Conversion of the acid **3** to the amide **5** also increased selectivity for KOR over DOR 3-fold. In contrast, the corresponding conversion of the acid in the D-Pro¹⁰ peptide **4** to give the amide (analog **8**) increased DOR affinity 6-fold, thus decreasing KOR vs. DOR selectivity.

In the linear analogs **6-12** modifications that could affect the C-terminal conformation were well tolerated by KOR, with these analogs exhibiting 2- to 4-fold higher KOR affinity than the parent peptide **5** (Table 1 and Figure 3). The introduction of a single modification in the C-terminus of [*N*-benzylTyr¹]Dyn A-(1-11)NH₂ (analog **6-8**) resulted in similar small increases (about 2-fold) in both KOR and MOR affinities regardless of the substitution

introduced. The only notable difference in the affinities of these three analogs was the 3-fold increase in DOR affinity as a result of incorporating D-Pro (analog **8**). Introduction of an additional modification in the C-terminus yielded analogs **9-11** with similar to slightly (up to 2-fold) higher KOR affinity than the monosubstituted analogs **6-8**; analog **12** with all three modifications exhibits KOR affinity similar to the monosubstituted derivatives **6-8** (Table 1 and Figure 3).

These modifications affected MOR and DOR affinities differently (Table 1). The MOR affinities of the linear analogs **6-12** were similar to one another, regardless of the substitutions, and generally about 2-fold higher than the parent peptide **5**. Since these changes in MOR affinity generally paralleled those for KOR, their selectivity for KOR over MOR varied by only 2-fold among these analogs. The changes in DOR affinity, however, were dependent on the type of substitution. While the *N*-MeArg⁷ and D-Ala⁸ modifications improved selectivity for KOR over DOR slightly, D-Pro¹⁰ increased DOR affinity in the C-terminal amide series, thereby reducing KOR vs. DOR selectivity. In peptides **9-12** containing substitutions in addition to D-Pro¹⁰, D-Ala⁸ but not *N*-MeArg⁷ alone decreased DOR affinity and restored selectivity for KOR over DOR. Thus, analog **11** containing D-Ala⁸ retained KOR vs. DOR selectivity, while the *N*-MeArg⁷ analog **10** exhibited higher DOR affinity and therefore lower KOR selectivity. The addition of D-Ala⁸ to *N*-MeArg⁷ and D-Pro¹⁰, resulting in analog **12**, restored the high KOR vs. DOR selectivity. Thus, substitution of D-Ala in position 8 appears to be important for maintaining high selectivity for KOR over DOR in these analogs.

In the cyclic peptides there was a marked difference in KOR affinity depending upon the position of the cyclic constraint. As reported previously,³⁵ the [5,8] cyclic peptide zyklophin (**13**) shows approximately a 4-fold decrease in KOR affinity ($K_i = 30$ nM) compared to the linear peptide **5**. Cyclization between residues 6 and 9 (cyclic analog **14**) led to a much larger decrease in KOR affinity ($K_i = 245$ nM) compared to the linear analog **5**. Zyklophin and **14** both show drastic decreases in MOR and DOR affinities compared to the linear peptide **5**. The decreases in MOR and DOR affinities were larger as a result of the [5,8] cyclization than due to the [6,9] cyclization. Thus the [5,8] cyclic analog zyklophin shows much higher affinity for KOR and much lower affinities for MOR and DOR compared to the [6,9] cyclic analog **14**, resulting in much greater KOR selectivity (Table 1). The affinities for all three opioid receptors for zyklophin (**13**) and analog **14**, with *N*-benzylation of Tyr¹, are lower than those for the unbenzylated *cyclo*[D-Asp⁵,Dap⁸]- (**17**) and *cyclo*[D-Asp⁶,Dap⁹]Dyn A-(1-13)NH₂ (**18**).³³ For the [5,8] cyclic derivative zyklophin, the KOR affinity is 4-fold lower than that of **17** ($K_i = 8$ nM), but for the [6,9] cyclic derivative **14** the KOR affinity is 100-fold lower than that of **18** ($K_i = 2.6$ nM), suggesting that the steric bulk of the *N*-benzyl group may have shifted **14** in the KOR binding site relative to **18**, leading to the large decrease in affinity. Interestingly, zyklophin shows much higher KOR selectivity over MOR compared to analog **17** (K_i ratio (KOR/MOR/DOR) = 1/9/412)³³ that does not possess the benzyl group on its *N*-terminal amine. Only a modest increase in selectivity for KOR over MOR and DOR upon *N*-benzylation of Tyr¹ was observed for the cyclic analog *cyclo*[D-Asp²,Dap⁵]Dyn A-(1-11)NH₂ ($K_i = 3.8$ nM, K_i ratio (KOR/MOR/DOR) = 1/5/56 for the *N*-benzylTyr¹ derivative vs. K_i ratio = 1/1.1/11 for the unbenzylated analog).⁴⁴

The linear analogs **15** and **16** were designed to evaluate the effect of the substitutions that were used to carry out the cyclizations between positions 5 and 8 or 6 and 9, respectively, on affinity and efficacy. To avoid effects due to the introduction of charged groups in the side chains, Asn and Dap(Ac) were introduced into these positions. Substitution of Asn and Dap(Ac) in positions 5 and 8, respectively, of **5** resulted in an 8-fold decrease in KOR affinity and a much larger decrease in MOR affinity compared to analog **5**. As reported earlier,³⁵ the [5,8] cyclization resulted in increases in KOR affinity and KOR vs. MOR

selectivity compared to the linear analog **15**. The linear peptide **16** with substitutions in positions 6 and 9 exhibits extremely low affinity for all three opioid receptors (Table 1). However, cyclization between these positions led to an 11-fold gain in KOR affinity for analog **14** compared to **16**, while the MOR affinity for **14** remained similar to the corresponding linear analog **16**. Thus the conformation induced by the cyclic constraint does not appear to be responsible for the low KOR affinity of **14**.

These analogs were evaluated for their efficacy in the AC assay using cloned rat KOR stably expressed on CHO cells. At concentrations of 10 μ M the linear peptides generally exhibit partial to full agonist activity at KOR (Figure 4), similar to that originally reported for peptide **3** (71% maximum inhibition of AC relative to Dyn A-(1-13)NH₂).²⁵ The linear analogs with different C-terminal modifications (**3-12**) showed very similar maximum inhibition of AC (70-90% relative to Dyn A-(1-13)NH₂) regardless of the type of substitution or number of substitutions. Thus, these changes in the C-terminal domain (*N*-MeArg⁷, D-Ala⁸, D-Pro¹⁰ and/ or C-terminal amidation) of linear [*N*-benzylTyr¹]Dyn A-(1-11) analogs had little effect on the efficacy of the analogs at cloned KOR in the AC assay. In contrast, the cyclic analog zyklophin (**13**) and the corresponding linear analog **15** show minimal efficacy in the AC assay, and as reported previously,³⁵ zyklophin exhibits antagonist activity ($K_B = 84$ nM) at KOR in this assay.³⁵ The linear analogs **14** and **16** were not tested for efficacy due to their low KOR affinities.

Conclusions

Various C-terminal modified analogs of [*N*-benzylTyr¹]Dyn A-(1-11) were synthesized to evaluate the effect of these modifications on opioid receptor affinity and efficacy. The effects on opioid receptor affinity varied depending upon the type of substitution and the receptor type. Interestingly, introducing a C-terminal amide functional group appeared to enhance KOR affinity slightly. While *N*-benzylation substantially decreased KOR affinity in the linear analogs, incorporation of additional modifications in the C-terminus increased KOR affinity by 2- to 4-fold in peptides **6-12** (Table 1 and Figure 3) such that the highest affinity *N*-benzylated analog had relatively high KOR affinity ($K_i = 2.2$ nM for peptide **10**). Generally the effects on MOR affinity were similar, so that the selectivity of **6-12** for KOR over MOR was within 2-fold that of **5**. The effects of the substituents on DOR affinity were more variable.

The most drastic changes in opioid receptor affinities occurred with the [5,8] and [6,9] cyclic analogs. Modifications in positions 5 and 8 were tolerated by KOR but not by MOR or DOR, leading to a large increase in KOR selectivity for zyklophin (**13**). The KOR affinity of zyklophin is only 4-fold lower compared to the cyclic peptide **17** without an *N*-benzyl group. In contrast, cyclization between positions 6 and 9 led to a very large decrease in KOR affinity. Peptide **18** without an *N*-benzyl group exhibits nanomolar affinity for KOR ($K_i = 2.6$ nM), suggesting that *N*-terminal alkylation shifts the peptide in the binding site resulting in the lower KOR affinities of **14** and **16**.

There was a marked difference in the effects of the modifications in the linear analogs **3-12** vs. peptides **13** and **15** on efficacy in the AC assay. The linear analogs **3-12** all exhibit similar efficacies regardless of the modifications in positions 7, 8 and/ or 10 that could affect peptide conformation. In contrast, the modifications in positions 5 and 8 in peptides **13** and **15** eliminated efficacy at KOR. These results are consistent with our hypothesis that appropriate modifications in the C-terminal domain can alter the efficacy of Dyn A analogs at KOR. To further elucidate the role of the conformational constraint and stereochemistry on efficacy, we are preparing a variety of analogs of zyklophin.

Because of their target specificity and high potency, opioid peptides and their analogs could be useful lead compounds for the development of therapeutic agents. The therapeutic use of peptide-based drugs has been limited because of their low oral bioavailability. However, alternative routes of administration such as inhalation⁴⁵ are being explored that could increase the acceptance of agents that aren't taken orally. Structural modifications to the endogenous peptides are necessary to impart sufficient metabolic stability for systemic administration and for the development of clinically useful peptides. Incorporation of unnatural amino acids along with conformational constraints, as are found in zyklophin, provides the improved enzymatic stability needed for *in vivo* studies. Metabolically stable, highly potent and KOR-selective peptide analogs can be used for a variety of central or peripheral effects depending upon their penetration of the blood-brain barrier.¹⁰ Dyn A-(1-11) analogs synthesized in our laboratory have shown blood-brain barrier penetration in the *in vitro* bovine brain microvessel endothelial cell (BBMEC) model.⁴⁶ KOR selective peptide antagonists such as zyklophin can serve as lead compounds for the development of potential treatments for opiate and cocaine addiction. Additional studies with this promising lead peptide antagonist are ongoing in our laboratories.⁴⁷

Experimental Section

Materials

The PAC-PEG-PS resin, PAL-PEG-PS resin, HOBt and DIEA were purchased from Applied Biosystems (Foster City, CA). HBTU was purchased from EMD Biosciences (San Diego, CA); HOAt and PyAOP were purchased from Applied Biosystems. Standard Fmoc-protected amino acids were purchased from Applied Biosystems, EMD Biosciences and Bachem Bioscience Inc. (King of Prussia, PA). Fmoc-Arg(Mtr), Fmoc-Dap(Mtt) and Tyr(OtBu) were purchased from EMD Biosciences. *N*-Benzytyrosine was synthesized as described in the Supporting Information. Piperidine, triisopropylsilane (TIS), and trifluoroacetic acid (TFA) were purchased from Aldrich Chemical Co. (Milwaukee, WI). All solvents (AcOH, MeCN (HPLC-grade), DMF, dichloromethane (DCM), MeOH (HPLC-grade), and tetrahydrofuran (THF)) used for peptide synthesis or high performance liquid chromatography (HPLC) analysis were obtained from either Burdick and Jackson, Inc. (Muskegon, MI) or EM Sciences (Gibbstown, NJ). TFA for HPLC analysis was purchased from Thermo-Fisher (Rockville, IL). Molecular weights of the compounds were determined by electrospray ionization mass spectrometry (ESI-MS) using a Thermoquest LCQ mass spectrometer (University of Maryland Baltimore) and/ or by fast atom bombardment mass spectrometry (FAB-MS) on a Kratos MS50RF mass spectrometer (Oregon State University).

Purification and analysis of the peptides

The crude peptides were purified by preparative reversed phase HPLC (Rainin HPXL HPLC system equipped with a Shimadzu SPD-10A detector) on a Vydac C18 column (10 μ , 300 Å, 21 \times 250 mm) equipped with a Vydac guard cartridge. For purification a linear gradient of 10-60% MeCN containing 0.1% TFA over 50 min, at a flow rate of 20 mL/min, was used. The purification was monitored at 214 nm. The purity of the final peptides was verified on a Vydac 218-TP column (5 μ , 300 Å, 4.6 \times 250 mm) equipped with a Vydac guard cartridge using a Beckman System Gold analytical HPLC, consisting of model 126 programmable solvent module and model 168 diode array detector module. Two systems, a linear gradient of 10-60% solvent B (solvent A, aqueous 0.1% TFA, and solvent B, MeCN containing 0.1% TFA) over 50 min, at a flow rate of 1 mL/min (system 1), and a linear gradient of 5-80% solvent B (solvent A, aqueous 0.1% TFA, and solvent B, MeOH containing 0.1% TFA) over 50 min, at a flow rate of 1.5 mL/min (system 2), were used for the analysis. The final purity of all peptides by both analytical systems was generally >98 % (see Supporting Information).

Peptide synthesis: General procedure for peptides 1-12, 15 and 16

All of the peptides were synthesized by coupling a 4-fold excess of Fmoc-protected amino acids (200 mM) on a Symphony Multiple Peptide Synthesizer (Rainin Inc.) using DMF as the solvent or a 3-fold excess of Fmoc-protected amino acids using a 1:1 mixture of DCM and DMF on a manual multiple peptide synthesizer ("CHOIR") constructed in house.⁴⁸ Peptides **2**, **5-12**, **15** and **16** were assembled on a high load PAL-PEG-PS resin (0.4 mmol/g, 200 mg) and peptides **13** and **14** were assembled on the low load PAL-PEG-PS resin (0.17 mmol/g, 200 mg). Peptides **1**, **3** and **4** were assembled on an FmocLys(Boc)-(hydroxymethyl)phenoxyacetic acid PEG-PS resin (PAC resin, 0.19 mmol/g, 200 mg). The side chains of the amino acids Lys, Arg and *N*-MeArg were protected by Boc, Pbf and Mtr groups, respectively. Following removal of the Fmoc protecting group using 20% piperidine in DMF the amino acids were coupled using HBTU (equimolar to the amino acid) and NMM (4-fold excess relative to the amino acid) as the coupling reagents for 2 h unless otherwise noted. *N*-Benzyltyrosine (1.5-3 equiv) was coupled to the resin-bound peptides using PyAOP, HOAt and DIEA (1:1:2 relative to the amino acid) in DMF (2-3 mL). Prior to coupling, complete dissolution of *N*-benzyltyrosine was achieved by warming the solution to 90 °C, followed by cooling to about 50-60 °C, and then adding PyAOP, HOAt and DIEA. Completion of the coupling reactions was indicated by the qualitative ninhydrin test and/or chloranil test.⁴⁹ During the synthesis of the Dyn A-(2-11) sequences, coupling of Fmoc-Arg(Pbf)OH (6-fold excess) in position 6 to *N*-MeArg(Mtr) at position 7 of the Dyn A-(7-11) segment was carried out manually using PyAOP, HOAt and DIEA (1:1:2 relative to the amino acid) in a 1:1 mixture of DMF and DCM. The coupling was complete in 12-24 h, as indicated by the chloranil test.

For peptides **15** and **16**, after coupling Fmoc-Dap(Mtt) at position 8 or 9, respectively, the Mtt group was selectively removed from the Dap side chain as follows: after swelling of the peptide-resin for 5 min in DCM (5 mL), the resin was treated with a mixture of 3% TFA and 5% TIS in DCM (3 × 10 min, 5 mL each). The resin was subsequently washed first with DCM and then with DMF (5 × 10 mL each). The free amine of the Dap side chain was then acetylated using 1-acetylimidazole (10-fold excess) and DIEA (2-fold excess) in DMF:DCM (3:1, 5 mL) for 1 h. The completion of the acylation was confirmed by the qualitative ninhydrin test. FmocD-Asn(Trt) was incorporated in positions 5 or 6, respectively, for peptides **15** and **16**. After removal of the *N*-terminal Fmoc protecting group using 20% piperidine in DMF (7 mL for 20 min), the rest of the amino acids were then coupled as described in the general procedure to complete the assembly of the peptides.

The peptides were generally cleaved from the resin using Reagent B³⁹ (88.5% TFA containing 2.5% water, 2.5% phenol and 5% TIS as scavengers) except for peptides containing *N*-MeArg. For these peptides containing the Mtr side chain protecting group on *N*-MeArg, 5% thioanisole and 2.5% 1,2-ethanedithiol (EDT) in TFA⁴⁰ were used along with 5% TIS and 2.5% phenol as scavengers. The peptides were filtered from the resin, and the filtrates diluted with 10% acetic acid (about 10-15 mL) and extracted with diethyl ether (3 × 20 mL). The ether extracts were back extracted with 10% acetic acid (20 mL). The combined aqueous extracts were pooled and lyophilized to give the crude peptides.

Synthesis of compounds 13 and 14

Peptide **14** was synthesized using the same synthetic strategy as peptide **13** described previously.³⁵ The cyclic peptides were assembled similar to the linear analogs except that Fmoc-D-Asp(Pip) and Fmoc-Dap(Mtt) were used in the positions involved in the cyclizations. For **13**, the amino acids from positions 5-11 and for **14**, the amino acids from positions 6-11 were coupled manually on the "CHOIR" as described above using HBTU and NMM as the coupling reagents. The Pip and Mtt groups were then selectively deprotected

with a mixture of 3% TFA and 5% TIS in DCM (3×10 min). The cyclization was carried out by mixing the resin with a mixture of PyAOP, HOAt and DIEA (3:3:6 relative to the resin substitution) dissolved in 1:1 DMF:DCM (4 mL) twice for a total of 24 h for **13** and three times for a total of 48 h for **14**. Any remaining unreacted free amine groups on Dap were acetylated as described above, and the rest of the peptides were assembled as described in the general procedure.

Pharmacological assays

Radioligand binding assays were performed as previously described³³ using cloned rat KOR and MOR and mouse DOR stably expressed on CHO cells. [³H]Diprenorphine ($K_D = 0.45$ nM), [³H]DAMGO ([D-Ala²,MePhe⁴,glyol]enkephalin) ($K_D = 0.49$ nM), and [³H]DPDPE (*cyclo*[D-Pen²,D-Pen⁵]enkephalin) ($K_D = 1.76$ nM) were used as radioligands in assays for KOR, MOR and DOR, respectively. Results are mean \pm SEM obtained from at least three independent experiments.

Adenylyl cyclase assays were performed as previously described²⁵ using cloned rat KOR stably expressed on CHO cells. Peptides were evaluated at 10 μ M compared to reference agonist Dyn A-(1-13)NH₂ (100 nM) to determine efficacy. Results are mean \pm SEM obtained from at least three independent experiments.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

The authors would like to thank Jennif Chandler and B. Miranda Thomas in Dr. Thomas Murray's laboratory for performing the pharmacological assays. This research was supported by grants R01 DA05195 and R01 DA018832 from the National Institute on Drug Abuse.

References

1. Trescot AM, Glaser SE, Hansen H, Benyamin R, Patel S, Manchikanti L. Effectiveness of Opioids in the Treatment of Chronic Non-cancer Pain. *Pain Physician*. 2008; 11:S181–200. [PubMed: 18443639]
2. Benyamin R, Trescot AM, Datta S, Buenaventura R, Adlaka R, Sehgal N, Glaser SE, Vallejo R. Opioid Complications and Side Effects. *Pain Physician*. 2008; 11:S105–120. [PubMed: 18443635]
3. Aldrich, JV.; Vigil-Cruz, S. Narcotic Analgesics. In: Abraham, D., editor. *Burger's Medicinal Chemistry and Drug Discovery*. Sixth. Vol. 6. John Wiley & Sons, Inc.; New York: 2003. p. 329-481.
4. Millan MJ. Kappa-opioid Receptors and Analgesia. *Trends Pharmacol Sci*. 1990; 11:70–76. [PubMed: 2156363]
5. Park HS, Lee HY, Kim YH, Park JK, Zvartau EE, Lee H. A Highly Selective Kappa-opioid Receptor Agonist with Low Addictive Potential and Dependence Liability. *Bioorg Med Chem Lett*. 2006; 16:3609–3613. [PubMed: 16650985]
6. Pfeiffer A, Brantl V, Herz A, Emrich HM. Psychotomimesis Mediated by Kappa Opiate Receptors. *Science*. 1986; 233:774–776. [PubMed: 3016896]
7. DeHaven-Hudkins DL, Dolle RE. Peripherally Restricted Opioid Agonists as Novel Analgesic Agents. *Curr Pharm Des*. 2004; 10:743–757. [PubMed: 15032700]
8. Vanderah TW, Largent-Milnes T, Lai J, Porreca F, Houghten RA, Menzaghi F, Wisniewski K, Stalewski J, Sueiras-Diaz J, Galyean R, Schteingart C, Junien JL, Trojnar J, Riviere PJ. Novel D-amino Acid Tetrapeptides Produce Potent Antinociception by Selectively Acting at Peripheral Kappa-opioid Receptors. *Eur J Pharmacol*. 2008; 583:62–72. [PubMed: 18282565]

9. Walker JS. Anti-inflammatory Effects of Opioids. *Adv Exp Med Biol.* 2003; 521:148–160. [PubMed: 12617572]
10. Aldrich JV, McLaughlin JP. Peptide Kappa Opioid Receptor Ligands: Potential for Drug Development. *AAPS J.* 2009; 11:312–322. [PubMed: 19430912]
11. Mague SD, Pliakas AM, Todtenkopf MS, Tomasiewicz HC, Zhang Y, Stevens WC Jr, Jones RM, Portoghese PS, Carlezon WA Jr. Antidepressant-like Effects of Kappa-opioid Receptor Antagonists in the Forced Swim Test in Rats. *J Pharmacol Exp Ther.* 2003; 305:323–330. [PubMed: 12649385]
12. Beardsley PM, Howard JL, Shelton KL, Carroll FI. Differential Effects of the Novel Kappa Opioid Receptor Antagonist, JD_{Tic}, on Reinstatement of Cocaine-seeking Induced by Footshock Stressors vs Cocaine Primes and its Antidepressant-like Effects in Rats. *Psychopharmacology (Berl).* 2005; 183:118–126. [PubMed: 16184376]
13. Zhang H, Shi YG, Woods JH, Watson SJ, Ko MC. Central Kappa-opioid Receptor-mediated Antidepressant-like Effects of nor-Binaltorphimine: Behavioral and BDNF mRNA Expression Studies. *Eur J Pharmacol.* 2007; 570:89–96. [PubMed: 17601558]
14. Knoll AT, Meloni EG, Thomas JB, Carroll FI, Carlezon WA Jr. Anxiolytic-like Effects of Kappa-opioid Receptor Antagonists in Models of Unlearned and Learned Fear in Rats. *J Pharmacol Exp Ther.* 2007; 323:838–845. [PubMed: 17823306]
15. Wittmann W, Schunk E, Rosskothien I, Gaburro S, Singewald N, Herzog H, Schwarzer C. Prodynorphin-derived Peptides are Critical Modulators of Anxiety and Regulate Neurochemistry and Corticosterone. *Neuropsychopharmacology.* 2009; 34:775–85. [PubMed: 18800067]
16. Rothman RB, Gorelick DA, Heishman SJ, Eichmiller PR, Hill BH, Norbeck J, Liberto JG. An Open-label Study of a Functional Opioid Kappa Antagonist in the Treatment of Opioid Dependence. *J Subst Abuse Treat.* 2000; 18:277–281. [PubMed: 10742642]
17. Carey AN, Borozny K, Aldrich JV, McLaughlin JP. Reinstatement of Cocaine Place-conditioning Prevented by the Peptide Kappa-opioid Receptor Antagonist Arodyn. *Eur J Pharmacol.* 2007; 569:84–89. [PubMed: 17568579]
18. Bennett MA, Murray TF, Aldrich JV. Identification of Arodyn, a Novel Acetylated Dynorphin A-(1-11) Analogue, as a Kappa Opioid Receptor Antagonist. *J Med Chem.* 2002; 45:5617–5619. [PubMed: 12477343]
19. Chavkin C, James IF, Goldstein A. Dynorphin is a Specific Endogenous Ligand of the κ Opioid Receptor. *Science.* 1982; 215:413–415. [PubMed: 6120570]
20. Chavkin C, Goldstein A. Specific Receptor for the Opioid Peptide Dynorphin: Structure-activity Relationships. *Proc Natl Acad Sci U S A.* 1981; 78:6543–6547. [PubMed: 6118865]
21. Gairin JE, Mazarguil H, Alvinerie P, Botanch C, Cros J, Meunier JC. N,N-Diallyl-tyrosyl Substitution Confers Antagonist Properties on the Kappa-selective Opioid Peptide [D-Pro¹⁰]dynorphin A(1-11). *Br J Pharmacol.* 1988; 95:1023–1030. [PubMed: 2905908]
22. Lemaire S, Parent P, Lapierre C, Michelot R. N,N-Diallylated Analogs of Dynorphin A-(1-13) as Potent Antagonists for the Endogenous Peptide and Selective Kappa Opioid Analgesics. *Prog Clin Biol Res.* 1990; 328:45–48. [PubMed: 1968273]
23. Choi H, Murray TF, DeLander GE, Caldwell V, Aldrich JV. N-Terminal Alkylated Derivatives of [D-Pro¹⁰]dynorphin A-(1-11) are Highly Selective for Kappa-opioid Receptors. *J Med Chem.* 1992; 35:4638–4639. [PubMed: 1361580]
24. Choi H, Murray TF, DeLander GE, Schmidt WK, Aldrich JV. Synthesis and Opioid Activity of [D-Pro¹⁰]Dynorphin A-(1-11) Analogues with N-Terminal Alkyl Substitution. *J Med Chem.* 1997; 40:2733–2739. [PubMed: 9276018]
25. Soderstrom K, Choi H, Berman FW, Aldrich JV, Murray TF. N-Alkylated Derivatives of [D-Pro¹⁰]dynorphin A-(1-11) are High Affinity Partial Agonists at the Cloned Rat Kappa-opioid Receptor. *Eur J Pharmacol.* 1997; 338:191–197. [PubMed: 9456002]
26. Schlechtingen G, Zhang L, Maycock A, DeHaven RN, Daubert JD, Cassel J, Chung NN, Schiller PW, Goodman M. [Pro³]Dyn A(1-11)-NH₂: A Dynorphin Analogue with High Selectivity for the Kappa Opioid Receptor. *J Med Chem.* 2000; 43:2698–2702. [PubMed: 10893307]
27. Lu Y, Nguyen TM, Weltrowska G, Berezowska I, Lemieux C, Chung NN, Schiller PW. [2',6'-Dimethyltyrosine]Dynorphin A(1-11)-NH₂ Analogues Lacking an N-terminal Amino Group:

- Potent and Selective Kappa Opioid Antagonists. *J Med Chem.* 2001; 44:3048–3053. [PubMed: 11543672]
28. Wan Q, Murray TF, Aldrich JV. A Novel Acetylated Analogue of Dynorphin A-(1-11) Amide as a Kappa-opioid Receptor Antagonist. *J Med Chem.* 1999; 42:3011–3013. [PubMed: 10447942]
29. Vig BS, Murray TF, Aldrich JV. A novel N-terminal Cyclic Dynorphin A Analogue *cyclo*^N,⁵[Trp³,Trp⁴,Glu⁵]dynorphin A-(1-11)NH₂ that Lacks the Basic N-terminus. *J Med Chem.* 2003; 46:1279–1282. [PubMed: 12672226]
30. Kawasaki AM, Knapp RJ, Walton A, Wire WS, Zalewska T, Yamamura HI, Porreca F, Burks TF, Hruby VJ. Syntheses, Opioid Binding Affinities, and Potencies of Dynorphin A Analogues Substituted in Positions, 1, 6, 7, 8 and 10. *Int J Pept Protein Res.* 1993; 42:411–419. [PubMed: 7906258]
31. Naqvi T, Haq W, Mathur KB. Structure-activity Relationship Studies of Dynorphin A and Related Peptides. *Peptides.* 1998; 19:1277–1292. [PubMed: 9786179]
32. Meyer JP, Collins N, Lung FD, Davis P, Zalewska T, Porreca F, Yamamura HI, Hruby VJ. Design, Synthesis, and Biological Properties of Highly Potent Cyclic Dynorphin A Analogues. Analogues Cyclized between Positions 5 and 11. *J Med Chem.* 1994; 37:3910–3917. [PubMed: 7966152]
33. Arttamangkul S, Ishmael JE, Murray TF, Grandy DK, DeLander GE, Kieffer BL, Aldrich JV. Synthesis and opioid Activity of Conformationally Constrained Dynorphin A Analogues. 2. Conformational Constraint in the “Address” Sequence. *J Med Chem.* 1997; 40:1211–1218. [PubMed: 9111295]
34. Paterlini G, Portoghese PS, Ferguson DM. Molecular Simulation of Dynorphin A-(1-10) Binding to Extracellular Loop 2 of the Kappa-opioid Receptor. A Model for Receptor Activation. *J Med Chem.* 1997; 40:3254–3262. [PubMed: 9379445]
35. Patkar KA, Yan X, Murray TF, Aldrich JV. [*N*^α-BenzylTyr¹,*cyclo*(D-Asp⁵,Dap⁸)]-dynorphin A-(1-11)NH₂ Cyclized in the “Address” Domain is a Novel Kappa-Opioid Receptor Antagonist. *J Med Chem.* 2005; 48:4500–4503. [PubMed: 15999987]
36. Carpino LA, El-Faham A, Minor CA, Alberizio F. Advantageous Application of Azabenzotriazole (Triazolopyridine)-based Coupling Reagents to Solid-Phase Peptide Synthesis. *J Chem Soc Chem Commun.* 1994:201–203.
37. Yue C, Thierry J, Potier P. 2-Phenyl Isopropyl Esters as Carboxyl Terminus Protecting Groups in the Fast Synthesis of Peptide Fragments. *Tetrahedron Lett.* 1993; 34:323–326.
38. Aletras A, Barlos K, Gatos D, Koutsogianni S, Mamos P. Preparation of the Very Acid-sensitive Fmoc-Lys(Mtt)-OH. Application in the Synthesis of Side-chain to Side-chain Cyclic Peptides and Oligolysine Cores Suitable for the Solid-phase Assembly of MAPs and TASP. *Int J Pept Protein Res.* 1995; 45:488–496. [PubMed: 7591489]
39. Solé NA, Barany G. Optimization of Solid-Phase Synthesis of [Ala⁸]-Dynorphin A. *J Org Chem.* 1992; 57:5399–5403.
40. King DS, Fields CG, Fields GB. A Cleavage Method Which Minimizes Side Reactions Following Fmoc Solid Phase Peptide Synthesis. *Int J Pept Protein Res.* 1990; 36:255–266. [PubMed: 2279849]
41. Wang JB, Johnson PS, Wu JM, Wang WF, Uhl GR. Human Kappa Opiate Receptor Second Extracellular Loop Elevates Dynorphin’s Affinity for Human mu/kappa Chimeras. *J Biol Chem.* 1994; 269:25966–25969. [PubMed: 7929306]
42. Yasuda K, Raynor K, Kong H, Breder CD, Takeda J, Reisine T, Bell GI. Cloning and Functional Comparison of Kappa and Delta Opioid Receptors from Mouse Brain. *Proc Natl Acad Sci U S A.* 1993; 90:6736–6740. [PubMed: 8393575]
43. Knapp RJ, Malatynska E, Collins N, Fang L, Wang JY, Hruby VJ, Roeske WR, Yamamura HI. Molecular Biology and Pharmacology of Cloned Opioid Receptors. *FASEB J.* 1995; 9:516–525. [PubMed: 7737460]
44. Vig, BS. Doctoral Dissertation. University of Maryland Baltimore; 2001. Synthesis and Pharmacological Evaluation of Dynorphin A Analogs Constrained in the “Message” Sequence.
45. Brugos B, Arya V, Hochhaus G. Stabilized Dynorphin Derivatives for Modulating Antinociceptive Activity in Morphine Tolerant Rats: Effect of Different Routes of Administration. *AAPS J.* 2004; 6:e36. [PubMed: 15760101]

46. Aldrich, JV.; Patkar, KA.; Chappa, AK.; Fang, W.; Audus, KL.; Lunte, SM.; Carey, AN.; McLaughlin, JP. Development of Centrally Acting Peptide Analogs: Structure-Transport Studies and Pharmacological Evaluation of Analogs of the Opioid Peptide Dynorphin A. In: Wilce, J., editor. Proceedings of the 4th International Peptide Symposium, Wilce, J Ed, 2007. Cairns, Queensland, Australia: 2007. www.peptideoz.org, M 64
47. Aldrich JV, Patkar KA, McLaughlin JP. Zyklophin, a Systemically Active KappaOpioidReceptor Peptide Antagonist with Short Duration of Action. Proc Natl Acad Sci U S A. in press.
48. Vig BS, Aldrich JV. An Inexpensive, Manually Operated, Solid-Phase, Parallel Synthesizer. Aldrichimica Acta. 2004; 37:2.
49. Vojkovsky T. Detection of Secondary Amines on Solid Phase. Pept Res. 1995; 8:236–237. [PubMed: 8527877]

ABBREVIATIONS

AC	adenylyl cyclase
Boc	<i>t</i> -butyloxycarbonyl
CPM	<i>N</i> -cyclopropylmethyl
Dap	2,3-diaminopropionic acid
DOR	delta opioid receptor
Dyn	dynorphin
Fmoc	9-fluorenylmethoxycarbonyl
GPI	guinea pig ileum
HBTU	2-(1 <i>H</i> -benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate
HOAt	1-hydroxy-7-azabenzotriazole
KOR	kappa opioid receptor
MOR	mu opioid receptor
Mtt	4-methyltrityl
PAC	Peptide Acid Linker
PAL	Peptide Amide Linker
Pip	2-phenylisopropyl
PyAOP	7-azabenzotriazol-1-yloxytris(pyrrolidino)phosphonium hexafluorophosphate
TFA	trifluoroacetic acid
Trt	trityl

HTyr-Gly-Gly-Phe-Leu-Arg-Arg-Ile-Arg-Pro-Lys¹¹-Leu-Lys¹³-Trp-Asp-Asn-GlnOH

Figure 1.
Dynorphin A

- 1 HTry-Gly-Gly-Phe-Leu-Arg-Arg-Ile-Arg-Pro-LysOH
- 2 HTyr-Gly-Gly-Phe-Leu-Arg-Arg-Ile-Arg-Pro-LysNH₂
- 3 PhCH₂Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Ile-Arg-Pro-LysOH
- 4 PhCH₂Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Ile-Arg-D-Pro¹⁰-LysOH
- 5 PhCH₂Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Ile-Arg-Pro-LysNH₂
- 6 PhCH₂Tyr-Gly-Gly-Phe-Leu-Arg-**N^αMe-Arg⁷**-Ile-Arg-Pro-LysNH₂
- 7 PhCH₂Tyr-Gly-Gly-Phe-Leu-Arg-Arg-**D-Ala⁸**-Arg-Pro-LysNH₂
- 8 PhCH₂Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Ile-Arg-**D-Pro¹⁰**-LysNH₂
- 9 PhCH₂Tyr-Gly-Gly-Phe-Leu-Arg-**N^αMe-Arg⁷-D-Ala⁸**-Arg-Pro-LysNH₂
- 10 PhCH₂Tyr-Gly-Gly-Phe-Leu-Arg-**N^αMe-Arg⁷-Ile-Arg-D-Pro¹⁰**-LysNH₂
- 11 PhCH₂Tyr-Gly-Gly-Phe-Leu-Arg-Arg-**D-Ala⁸-Arg-D-Pro¹⁰**-LysNH₂
- 12 PhCH₂Tyr-Gly-Gly-Phe-Leu-Arg-**N^αMe-Arg⁷-D-Ala⁸-Arg-D-Pro¹⁰**-LysNH₂
- 13 (zyklophin) PhCH₂Tyr-Gly-Gly-Phe-**D-Asp⁵-Arg-Arg-Dap⁸**-Arg-Pro-LysNH₂
- 14 PhCH₂Tyr-Gly-Gly-Phe-Leu-**D-Asp⁶-Arg-Ile-Dap⁹**-Pro-LysNH₂
- 15 PhCH₂Tyr-Gly-Gly-Phe-**D-Asn⁵-Arg-Arg-Dap(Ac)⁸**-Arg-Pro-LysNH₂
- 16 PhCH₂Tyr-Gly-Gly-Phe-Leu-**D-Asn⁶-Arg-Ile-Dap(Ac)⁹**-Pro-LysNH₂

Figure 2. Dyn A-(1-11) and Its Analogs. Modifications in peptides **4-16** were made in the “address” sequence (italicized in **3**). Structural differences from peptide **5** are highlighted in bold in subsequent analogs.




Figure 3.
KOR Affinities of [*N*-benzylTyr¹]Dyn A-(1-11) Analogs





Figure 4. Efficacies of [*N*-benzylTyr¹]Dyn A-(1-11) Analogs as Inhibitors of Adenylyl cyclase (AC) in CHO Cells Expressing KOR.^a

^a Percent AC inhibition relative to Dyn A-(1-13)NH₂ (100%)



Scheme 2.
Solid Phase Synthesis of Cyclic Peptide **14**

Table 1

Opioid Receptor Binding Affinities of Dyn A-(1-11) analogs

Peptide	K_i (nM) \pm SEM			K_i Ratio
	KOR	MOR	DOR	KOR/MOR/DOR
1 Dyn A-(1-11)	1.11 \pm 0.36	3.50 \pm 0.42	8.18 \pm 0.09	1/3/7
2 Dyn A-(1-11)NH ₂	0.57 \pm 0.01	1.85 \pm 0.52	6.18 \pm 1.01	1/3/11
3 [<i>N</i> -benzylTyr ¹]Dyn A-(1-11)OH	14.8 \pm 4.5	98.1 \pm 9.8	345 \pm 12	1/7/23
4 [<i>N</i> -benzylTyr ¹ ,D-Pro ¹⁰]Dyn A-(1-11)OH	15.5 \pm 1.0	159 \pm 30	970 \pm 131	1/10/63
5 [<i>N</i> -benzylTyr ¹]Dyn A-(1-11)NH ₂	8.17 \pm 2.16	84.9 \pm 16.5	474 \pm 47	1/10/58
Analogues of [<i>N</i> -benzylTyr ¹]Dyn A-(1-11)NH ₂ , 5				
6 [<i>N</i> ^α -MeArg ⁷]	3.99 \pm 1.09	49.9 \pm 9.7	345 \pm 31	1/13/86
7 [D-Ala ⁸]	4.64 \pm 0.91	51.2 \pm 3.0	372 \pm 25	1/11/80
8 [D-Pro ¹⁰]	4.56 \pm 0.42	45.1 \pm 4.9	148 \pm 5	1/10/32
9 [<i>N</i> ^α -MeArg ⁷ ,D-Ala ⁸]	3.11 \pm 0.64	44.8 \pm 7.3	458 \pm 130	1/14/147
10 [<i>N</i> ^α -MeArg ⁷ ,D-Pro ¹⁰]	2.17 \pm 0.22	36.5 \pm 3.6	120 \pm 24	1/17/55
11 [D-Ala ⁸ ,D-Pro ¹⁰]	3.10 \pm 0.98	46.1 \pm 8.6	337 \pm 54	1/15/109
12 [<i>N</i> ^α -MeArg ⁷ ,D-Ala ⁸ ,D-Pro ¹⁰]	4.40 \pm 0.75	69.8 \pm 0.7	665 \pm 174	1/16/151
13 ^a <i>cyclo</i> [D-Asp ⁵ ,Dap ⁸] (zyklophin)	30.3 \pm 1.9	5880 \pm 1420	> 10,000	1/194/>330
14 <i>cyclo</i> [D-Asp ⁶ ,Dap ⁹]	245 \pm 37	1190 \pm 270	3663 \pm 660	1/5/15
15 ^a [D-Asn ⁵ ,Dap(Ac) ⁸]	66.9 \pm 5.9	1660 \pm 440	> 10,000	1/25/149
16 [D-Asn ⁶ ,Dap(Ac) ⁹]	2838 \pm 302	1500 \pm 310	4640 \pm 340	2/1/3

^aFrom ref 35.